CTMA Expands to Rheumatology

Article

CTMA has announced that it is expanding its CT-SCOUT™ technology offering into a second therapeutic area–rheumatology. CT-SCOUT™, the company’s multi-device platform that allows health care professionals (HCP) to identify trial candidates, will now be available for sites, sponsors and contract research organizations (CROs) in three rheumatological indications: Rheumatoid Arthritis, Ankylosing Spondylarthritis and Psoriatic Rheumatism.

Read more about the announcement here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
© 2023 MJH Life Sciences

All rights reserved.